These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Health-related quality of life 3 years after high-dose intensity-modulated radiotherapy with gold fiducial marker-based position verification.
    Author: Lips IM, van Gils CH, van der Heide UA, Kruger AE, van Vulpen M.
    Journal: BJU Int; 2009 Mar; 103(6):762-7. PubMed ID: 18990145.
    Abstract:
    OBJECTIVE: To evaluate the change in quality of life (QoL) 3 years after high-dose intensity-modulated radiotherapy (IMRT) using gold fiducial marker-based position verification in patients with locally advanced prostate cancer. PATIENTS AND METHODS: Between October 2003 and November 2004, 95 patients with locally advanced prostate cancer were treated with 76 Gy IMRT with gold-fiducial marker-based position verification. Before treatment (baseline) and 1, 6 and 36 months after RT the QoL was measured using the RAND-36, the European Organization for Research and Treatment of Cancer (EORTC) core questionnaire (QLQ-C30(+3)) and the prostate tumour-specific module (EORTC QLQ-PR25). Changes in QoL with time of > or =10 points were considered clinically relevant. RESULTS: After 3 years there was a statistically significant improvement in QoL for emotional role restriction and functioning, change in health, mental health and insomnia, compared with baseline. Emotional role restriction increased by >10 points and was therefore clinically relevant, while all other differences were of <10 points. There was a statistically significant deterioration of QoL after 3 years in physical and cognitive functioning, bowel symptoms/function and sexual activity. Only the sexual activity QoL score changed by 12 points and was therefore the only meaningful deterioration in QoL at 3 years after treatment. CONCLUSION: IMRT and accurate position verification provide the possibility to deliver a high irradiation dose to the prostate without clinically relevant deterioration in long-term QoL, except for a persistent decrease in sexual activity score.
    [Abstract] [Full Text] [Related] [New Search]